Abstract c-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …

Chemotherapy remains the mainstay of treatment in the majority of solid and haematological
malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and …

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies and is
characterized by a unique tumor microenvironment (TME) consisting of an abundant stromal …

Background Dysregulated expression and activation of receptor tyrosine kinases (RTKs) are
associated with a range of human cancers. However, current RTK-targeting strategies exert …

Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer related
death. The urgent need for effective therapies is highlighted by the lack of adequate …

Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth most common cause of cancer-
related death and is the most lethal of common malignancies with a five-year survival rate …

With the advent of cancer immunotherapies, significant advances have been made in the
treatment of many tumor types including melanoma, lung cancer, squamous cell carcinoma …

MET receptor has emerged as a druggable target across several human cancers. Agents
targeting MET and its ligand hepatocyte growth factor (HGF) including small molecules such …

Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy,
with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and …

The hedgehog pathway, which plays a significant role in embryonic development and stem
cell regulation, is activated in gastrointestinal cancers. Chemotherapy is widely used in …